Bacteremia due to Bacteroides fragilis group: Distribution of species, β-lactamase production, and antimicrobial susceptibility patterns

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 148-153

  Aldridge, Kenneth E ^a   Ashcraft, Deborah ^a   O'Brien, Megan ^a   Sanders, Charles V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFMETAZOLE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CLINDAMYCIN; ERTAPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; DILUTION; ENZYME SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0037226376     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.148-153.2003     Document Type: Article

References (30)

1. Aldridge, K. E., C. V. Sanders, A. C. Lewis, and R. L. Marier. 1983. Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production. J. Med. Microbiol. 16:75-82.
2. Aldridge, K. E., A. Henderberg, D. D. Schiro, and C. V. Sanders. 1988. Susceptibility of Bacteroides fragilis group isolates to broad-spectrum β-lactams, clindamycin, and metronidazole: rates of resistance, cross-resistance, and importance of β-lactamase production. Adv. Ther. 5:273-282.
3. Aldridge, K. E. 1992. In vitro susceptibility of Bacteroides fragilis group strains from abscesses, body fluids, and wound/tissue sources. Drug Investig. 4(Suppl. 1):1-6.
4. Aldridge, K. E. 1993. Activity of β-lactam-β-lactamase inhibitor combinations against the Bacteroides fragilis group: increased resistance among B. distasonis strains, p. 478-479. In Proceedings of the 18th International Congress of Chemotherapy. International Congress of Chemotherapy, Stockholm, Sweden.
5. Aldridge, K. E., M. Gelfand, L. B. Reller, L. W. Ayers, C. L. Pierson, F. Schoenknect, R. C. Tilton, J. Wilkins, A. Henderberg, D. D. Schiro, M. Johnson, A. Janney, and C. V. Sanders. 1994. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin, and metronidazole in the United States. Diagn. Microbiol. Infect. Dis. 18:235-241.
6. Aldridge, K. E. 1995. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections. Am. J. Surg. 169(Suppl. 5A):2S-7S.
7. Aldridge, K. E., D. Ashcraft, K. Cambre, C. L. Pierson, S. G. Jenkins, and J. E. Rosenblatt. 2001. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. 45:1238-1243.
8. Bandoh, K., K. Ueno, K. Watanabe, and N. Kato. 1993. Susceptibility patterns and resistance to imipenem in the B. fragilis group species in Japan: a 4-year study. Clin. Infect. Dis. 16(Suppl. 4):S382-S386.
9. Brook, I. 1990. The clinical importance of all members of the Bacteroides fragilis group. J. Antimicrob. Chemother. 25:473-474.
10. Chow, A. W., and L. B. Guze. 1974. Bacteroidaceae bacteremia: clinical experience with 112 patients. Medicine 53:93-126.
11. Cuchural, G. J., Jr., F. P. Tally, N. V. Jacobus, K. Aldridge, T. Cleary, S. M. Finegold, G. Hill, P. Iannini, J. P. O'Keefe, C. Pierson, D. Crook, T. Russo, and D. Hecht. 1988. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob. Agents Chemother. 32:717-722.
12. Daniel, W. W. 1995. Biostatistics: a foundation for analysis in the health sciences, 6th ed. John Wiley & Sons, Inc., New York, N.Y.
13. Ednie, L. M., M. R. Jacobs, and P. C. Appelbaum. 1998. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob. Agents Chemother. 42:2459-2462.
14. Galán, J. G., M. Reig, A. Navas, F. Baquero, and J. Blázquez. 2000. ACI-1 from Acidaminococcus fermentans: characterization of the first β-lactamase in anaerobic cocci. Antimicrob. Agents Chemother. 44:3144-3149.
15. Gill, C. J., J. J. Jackson, L. S. Gerckens, B. A. Pelak, R. K. Thompson, J. G. Sundelof, H. Kropp, and H. Rosen. 1998. In vitro activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-748-345). Antimicrob. Agents Chemother, 42:1996-2001.
16. Holdeman, L. V., E. P. Cato, and W. E. C. Moore. 1977. Anaerobe laboratory manual, 4th ed. Virginia Polytechnic Institute and State University, Blacksburg, Va.
17. Kesado, T. L. Lindqvist, M. Hedberg, K. Tunér, and C. E. Nord. 1989. Purification and characterization of a new β-lactamase from Clostriditini butyricum. Antimicrob. Agents Chemother. 33:1302-1307.
18. Könöen, E., S. Nyfors, J. Mätö, S. Asikainen, and H. Joursimies-Somer. 1997. β-Lactamase production by oral pigmented Prevotella species isolated from young children. Clin. Infect. Dis. 25:S272-S274.
19. Montravers, P., R. Gauzit, C. Muller, J. P. Marmuse, A. Fichelle, and J. M. Desmonts. 1996. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery, affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. 23:486-494.
20. National Committee for Clinical Laboratory Standards. 2001. Approved standard M11-A5. Methods for antimicrobial susceptibility testing of anaerobic bacteria. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. Nguyen, M. H., V. L. Yu, A. J. Morris, L. McDermott, M. W. Wagener, L. Harrell, and D. R. Snydman. 2000. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30:870-876.
22. Nord, C. E., L. Lindqvist, B. Olsson-Liljequist, and K. Tuner. 1985. Betalactamases in anaerobia bacteria. Scand. J. Infect. Dis. 46(Suppl.):57-63.
23. Parker, A. C., and C. J. Smith. 1993. Genetic and biochemical analysis of a novel Ambler class A β-lactamase responsible for cefoxitin resistance in Bacteroides species. Antimicrob. Agents Chemother. 37:1028-1036.
24. Patey, O., E. Varon, T. Prazuck, I. Podglajen, A. Duhlanchet, L. Dubreuil, and J. Breuil. 1994. Multicentre survey in France of the antimicrobial susceptibilities of 416 blood culture isolates of the Bacteroidesfragilis group. J. Antimicrob. Chemother. 33:1029-1034.
25. Redondo, M. C., M. D. J. Arbo, J. Grindlinger, and D. R. Snydman. 1995. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin. Infect. Dis. 20:1492-1946.
26. Rotimi, V. O., M. Khoursheed, J. S. Brazier, W. Y. Jamal, and F. B. Khodakhast. 1999. Bacteroides species highly resistant to metronidazole: an emerging clinical problem? Clin. Microbiol. Infect. 5:166-169.
27. Smith, C. J., T. K. Bennett, and A. C. Parker. 1994. Molecular and genetic analysis of the Bacteroides uniformis cephalosporinase gene, cb1A, encoding the species-specific β-lactamase. Antimicrob. Agents Chemother. 38:1711-1715.
28. Snydman, D. R., N. J. Jacobus, L. A. McDermott, S. Supran, G. J. Cuchural, Jr., S. Finegold, L. Harrell, D. W. Hecht, P. Iannini, S. Jenkins, C. Pierson, J. Rihs, and S. L Gorbach. 1999. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob. Agents Chemother. 43:2417-2422.
29. Summanen, P., E. J. Baron, D. Citron, C. Strong, H. M. Wexler, and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual, 5th ed. Star Publishing Company, Belmont, Calif.
30. Tunér, K., L. Lindqvist, and C. E. Nord. 1985. Purification and properties of a novel β-lactamase from Fusobacterium nucleatum. Antimicrob. Agents Chemother. 27:943-947.